Introduction

Introducing the 1st generation biosimilars of Polus

These are our target biosimilar products.We are aiming to establish four different biosimilar products. Our primary target products are Insulin Glargine and Somatropin, and secondary target products are Ranibizumab and Insulin Lispro.

Stage Code Target Biosimilar Therapeutic Area
Primary Targets PDP808 Insulin Glargine Diabetes
PDP805 Somatropin Growth Hormone Deficiency
Secondary Targets PDP807 Ranibizumab Macular Degeneration
PDP815 Insulin Lispro Diabetes

Description

Introducing the 1st generation biosimilars of Polus

PDP808 (Insulin Glargine Biosimilar) Insulin Glargine, a type of recombinant insulin, is a long-acting insulin that is administered once a day to diabetic patients in order to continuously control the blood glucose level for 24 hours. Insulin Glargine is a blockbuster product that was ranked within the top five global biologics sales in 2015. In the same year, the global market for long-acting insulin was about $15.9 billion, in which Lantus®(Insulin Glargine) was the largest with about $11.3 billion, followed by Levemir®(Insulin Determir) with about $4.2 billion.

PDP805 (Somatropin Biosimilar) Somatropin is the recombinant human growth hormone used in the treatment of pediatric growth hormone deficiency, adult growth hormone deficiency, Turner syndrome and other illnesses. The total label market for Somatropin was approximately $3.5 billion in 2015, whereas off-label market would generally be considered to exceed the label market.

PDP807 (Ranibizumab Biosimilar) Ranibizumab is a biologic drug that is administered to patients for the treatment of neovascular (wet) age-related macular degeneration or macular edema by retinal vein occlusion. Ranibizumab is one of the top biologics in the treatment for macular degeneration.

PDP815 (Insulin Lispro Biosimilar) Insulin Lispro is a short-acting insulin molecule administered for diabetic patients before and after the meals in order to control the blood glucose level for 2 to 5 hours. Insulin Lispro was ranked 11th in terms of global sales for biologics. Humalog®(Insulin Lispro) is a blockbuster biologic product that reached $4.3 billion sales out of $13.6 billion total short-acting insulin market.

※ Source : IMS Health MIDAS, 2015